about
DOE Optimization of Nano-based Carrier of Pregabalin as Hydrogel: New Therapeutic &Chemometric Approaches for Controlled Drug Delivery SystemsPharmacokinetic Evaluation of Empagliflozin in Healthy Egyptian Volunteers Using LC-MS/MS and Comparison with Other Ethnic PopulationsLiquid chromatographic determination of sitagliptin either alone or in ternary mixture with metformin and sitagliptin degradation product.LC-MS/MS Determination of Empagliflozin and Metformin.Comparative study between different simple methods manipulating ratio spectra for the analysis of alogliptin and metformin co-formulated with highly different concentrations.Suitability of various chromatographic and spectroscopic techniques for analysis and kinetic degradation study of trelagliptin.Green Pharmaceutical Analysis of Drugs Coformulated with Highly Different Concentrations Using Spiking and Manipulation of Their Ratio Spectra.Bioavailability Study of Niosomal Salbutamol Sulfate in Metered Dose Inhaler: Controlled Pulmonary Drug Delivery.A guide for using experimental design in chromatographic method development: applied to the analysis of selected anti-diabetic pharmaceutical combinations.Comparative study between UHPLC-UV and UPLC-MS/MS methods for determination of alogliptin and metformin in their pharmaceutical combination.Development and validation of simple spectrophotometric and chemometric methods for simultaneous determination of empagliflozin and metformin: Applied to recently approved pharmaceutical formulation.Factorial design optimization of micelle enhanced synchronous spectrofluorimetric assay of Omarigliptin: Applied to content uniformity testing and in vitro drug release.Different Spectrophotometric Methods for Simultaneous Determination of Trelagliptin and Its Acid Degradation Product.Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent.Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agentsStructural re-positioning, in silico molecular modelling, oxidative degradation, and biological screening of linagliptin as adenosine 3 receptor (ADORA3) modulators targeting hepatocellular carcinoma.Enhanced LC-MS/MS determination of alogliptin and metformin in plasma: Application to a pharmacokinetic study
P50
Q41776274-1487EF33-8B9A-4167-9F9E-8194A9B21DADQ42234492-D6F1935C-5DE2-4C9A-B202-693D34C62485Q44128764-1313474D-D7EC-41CF-B7D0-20EF97572E2EQ46390989-AAEDC055-B438-40AD-8AC8-7CEDA058DF5CQ46646960-F83A16F4-7659-4145-B6F8-A59C527362B3Q47133131-8556379B-06D9-4925-8E70-B7270A42FF79Q48708450-AA94B2B9-FBF1-4EB3-968B-0C5A2AEB0BF1Q49926252-3D16263D-C440-4C57-9AC8-5A6A7A43BB2DQ50017871-E87BF927-0C1F-4EEA-A3DA-D2B08B6EFDB3Q50018835-120E334F-C225-44A9-A6C7-828911143DBAQ50629288-3647F982-52A0-43E0-BEA9-39DD4E4089D9Q51731442-DD33862B-DAF3-44D2-9BC1-512ECD7DE757Q52381659-AFA99680-5283-4F93-B374-E5AC82CE5AA5Q55190915-214DA9CD-34E7-495E-A448-4B0603CB761EQ64076324-297FAA1B-EC14-4255-9D38-B6C0765BA20EQ64945049-03C602A5-5E2C-49A7-AF6A-17B901A711EBQ70768370-FA4A3BCC-4087-4053-825F-DD5CC56DD3D8
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Bassam M Ayoub
@es
Bassam M. Ayoub
@en
Bassam M. Ayoub
@nl
Bassam M. Ayoub
@sl
type
label
Bassam M Ayoub
@es
Bassam M. Ayoub
@en
Bassam M. Ayoub
@nl
Bassam M. Ayoub
@sl
altLabel
Bassam M Ayoub
@en
prefLabel
Bassam M Ayoub
@es
Bassam M. Ayoub
@en
Bassam M. Ayoub
@nl
Bassam M. Ayoub
@sl
P1053
I-6311-2017
P106
P1153
37050524500
P21
P31
P3829
P3835
bassam-ayoub2
P496
0000-0002-3265-1567
P569
2000-01-01T00:00:00Z